Faron Pharmaceuticals Oy (LON:FARN – Get Free Report)’s stock price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 42.71 and traded as low as GBX 40.15. Faron Pharmaceuticals Oy shares last traded at GBX 40.15, with a volume of 15,908 shares trading hands.
Faron Pharmaceuticals Oy Trading Down 2.4%
The business has a 50 day simple moving average of GBX 42.71 and a 200-day simple moving average of GBX 70.29. The company has a current ratio of 0.84, a quick ratio of 1.09 and a debt-to-equity ratio of -133.35. The stock has a market capitalization of £81.15 million, a price-to-earnings ratio of -1.81 and a beta of 1.12.
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
See Also
- Five stocks we like better than Faron Pharmaceuticals Oy
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
